Published in Br J Haematol on March 01, 2005
Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. Biol Blood Marrow Transplant (2013) 1.51
Peripheral blood stem cell mobilization: new regimens, new cells, where do we stand. Curr Opin Hematol (2008) 1.33
Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives. Biol Blood Marrow Transplant (2007) 1.31
Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation. Clin Exp Immunol (2007) 1.20
What is the role for donor natural killer cells after nonmyeloablative conditioning? Biol Blood Marrow Transplant (2009) 1.16
The effect of the composition of unrelated donor bone marrow and peripheral blood progenitor cell grafts on transplantation outcomes. Biol Blood Marrow Transplant (2009) 0.92
Correlation of infused CD3+CD8+ cells with single-donor dominance after double-unit cord blood transplantation. Biol Blood Marrow Transplant (2012) 0.91
Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica (2016) 0.84
Risk assessment before allogeneic hematopoietic cell transplantation for older adults with acute myeloid leukemia. Expert Rev Hematol (2013) 0.82
B cells and transplantation: an educational resource. Biol Blood Marrow Transplant (2009) 0.80
Donor Cell Composition and Reactivity Predict Risk of Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. J Immunol Res (2016) 0.75
Transplantation Dose Alters the Differentiation Program of Hematopoietic Stem Cells. Cell Rep (2016) 0.75
Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med (1999) 22.81
Purification and characterization of mouse hematopoietic stem cells. Science (1988) 15.99
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation (1974) 10.91
Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med (1980) 9.64
Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst (1992) 6.18
Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med (2001) 5.59
Lactation and a reduced risk of premenopausal breast cancer. N Engl J Med (1994) 5.37
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood (2001) 4.65
Long-term survival among men with conservatively treated localized prostate cancer. JAMA (1995) 4.24
Bone-marrow transplantation (second of two parts). N Engl J Med (1975) 4.11
Bone marrow transplantation for sickle cell disease. N Engl J Med (1996) 4.02
Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood (2000) 3.85
Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med (1982) 3.78
Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med (1979) 3.59
Bone-marrow transplantation (first of two parts). N Engl J Med (1975) 3.33
Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med (1986) 3.22
Clonal analysis of hematopoietic stem-cell differentiation in vivo. Proc Natl Acad Sci U S A (1991) 3.14
Pregnancy termination in relation to risk of breast cancer. JAMA (1996) 3.04
Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood (1981) 3.03
Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood (1999) 2.97
Retracted Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med (1995) 2.97
Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc (1974) 2.95
The canine major histocompatibility complex. Supertypic specificities defined by the primed lymphocyte test (PLT). Immunogenetics (1984) 2.72
Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med (1981) 2.61
The impact of co-morbidity on life expectancy among men with localized prostate cancer. J Urol (1996) 2.57
Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med (1989) 2.42
Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol (2000) 2.38
One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood (1977) 2.36
Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med (1998) 2.36
Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood (1996) 2.30
Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med (1985) 2.30
Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. Blood (1976) 2.29
Mouse hematopoietic stem-cell antigen Sca-1 is a member of the Ly-6 antigen family. Proc Natl Acad Sci U S A (1989) 2.24
Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst (1995) 2.24
Syndrome of idiopathic hyperammonemia after high-dose chemotherapy: review of nine cases. Am J Med (1988) 2.19
Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood (1992) 2.14
A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 2.11
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant (2001) 2.10
Mouse hematopoietic stem cells. Blood (1991) 2.07
General relative risk functions for case-control studies. Am J Epidemiol (1985) 2.07
Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med (2000) 2.05
Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood (2001) 2.04
Culture of phenotypically defined hematopoietic stem cells and other progenitors at limiting dilution on Dexter monolayers. Blood (1991) 2.00
Surgery-related factors and local recurrence of Wilms tumor in National Wilms Tumor Study 4. Ann Surg (1999) 1.97
Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia (2006) 1.92
Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol (1990) 1.91
A clinical trial of anti-idiotype therapy for B cell malignancy. Blood (1985) 1.91
Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med (1983) 1.89
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (2006) 1.84
A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. Blood (1979) 1.83
Technique for human marrow grafting. Blood (1970) 1.83
Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease. Blood (1997) 1.80
Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood (1995) 1.79
Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood (1996) 1.77
Allogeneic marrow grafting for treatment of aplastic anemia. Blood (1974) 1.76
Ovarian function following marrow transplantation for aplastic anemia or leukemia. J Clin Oncol (1988) 1.72
Histocompatibility testing of dog families with highly polymorphic microsatellite markers. Transplantation (1996) 1.72
Marrow transplantation for thalassaemia. Lancet (1982) 1.71
Establishment of pregnancy after removal of sperm antibodies in vitro. BMJ (1992) 1.68
Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood (2001) 1.66
Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood (1997) 1.64
Body size and risk of breast cancer. Am J Epidemiol (1997) 1.63
Long-term outcome after marrow transplantation for severe aplastic anemia. Blood (1998) 1.63
Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol (1995) 1.59
Primary treatment of acquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy. Seattle Bone Marrow Transplant Team. Ann Intern Med (1997) 1.59
Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med (1981) 1.56
Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control (2000) 1.56
In vivo effects of murine hybridoma monoclonal antibody in a patient with T-cell leukemia. Blood (1981) 1.52
DLA-DRB1 and DLA-DQB1 histocompatibility typing by PCR-SSCP and sequencing. Tissue Antigens (1998) 1.51
Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia (2006) 1.51
Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol (1995) 1.50
Interstitial pneumonia and cytomegalovirus infection as complications of human marrow transplantation. Transplantation (1973) 1.48
Radiation myelitis following allogeneic stem cell transplantation and consolidation radiotherapy for non-Hodgkin's lymphoma. Bone Marrow Transplant (2000) 1.46
Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Ann Intern Med (1983) 1.44
Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med (1979) 1.44
Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma (1985) 1.43
Bile secretory apparatus: evidence for a vesicular transport mechanism for proteins in the rat, using horseradish peroxidase and [125I]insulin. Gastroenterology (1980) 1.42